Optimising survival in metastatic castration-resistant prostate cancer (mCRPC)

Industry session by SANOFI GENZYME

  • Location:
    Room London, North Hall (Level 1)
  • Chair:
     B. Tombal, Brussels (BE)
Welcome and introduction
 B. Tombal, Brussels (BE)
Are we targeting prostate cancer heterogeneity in the right way?
 B. Tombal, Brussels (BE)
mCRPC in 2017 - Lessons from clinical trials and perspectives
 J. De Bono, Sutton (GB)
mCRPC in 2017 - From clinical trials to real-life practice
 S. Oudard, Paris (FR)
mCRPC in 2017 - A closer look to senior adults
 N. Mottet, Saint-√Čtienne (FR)
Discussion and closing remarks
 B. Tombal, Brussels (BE)